Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1542442 | 1.00 | LSS (0.51) | LSSMEN1KMT2ACHRNA7ALDH1A1 | |
| SCHEMBL5419769 | 1.00 | LSS (0.51) | LSSMEN1KMT2ACHRNA7ALDH1A1 | |
| SCHEMBL5649311 | 0.96 | LSS (0.54) | LSSMEN1KMT2ACHRNA7ALDH1A1 | |
| Hydrochloric Acid SCHEMBL9469824 | 0.94 | LSS (0.53) | LSSMEN1KMT2ACHRNA7ALDH1A1 | |
| SCHEMBL5710652 | 0.88 | MEN1 (0.52) | LSSMEN1KMT2ACHRNA7ALDH1A1 | |
| SCHEMBL9469598 | 0.80 | MEN1 (0.63) | LSSMEN1KMT2A | |
| SCHEMBL4204692 | 0.80 | LSS (0.55) | LSSCHRNA7 | |
| Hydrochloric Acid SCHEMBL9469086 | 0.79 | MEN1 (0.62) | LSSMEN1KMT2A | |
| SCHEMBL5418233 | 0.79 | LSS (0.53) | LSSCHRNA7 | |
| SCHEMBL1542294 | 0.79 | LSS (0.53) | LSSCHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308875-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives as .alpha.7 nAChR modulators | Abbott Laboratories (US) | 2011-04-13 | — | — | EP | disclosed |
| US-7655657-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2010-02-02 | — | — | US | disclosed |
| US-20080064703-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
| US-7309699-B2 | 3-Quinuclidinyl amino-substituted biaryl derivatives | ABBOTT LABORATORIES (US) | 2007-12-18 | — | — | US | disclosed |
| US-20070275975-A1 | 3-QUINUCLIDINYL AMINO-SUBSTITUTED BIARYL DERIVATIVES | JI JIANGUO | 2007-11-29 | — | — | US | disclosed |
| EP-1824848-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED QUINUCLIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2007-08-29 | — | — | EP | disclosed |
| US-20070060588-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES | 2007-03-15 | — | — | US | disclosed |
| WO-2006065233-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED QUINUCLIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20050245531-A1 | 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1H-indole; attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease, senile dementia, AIDS dementia, Pick's Disease, dementia associated with Down's syndrome; alpha 7 nAChR ligands modulators | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | disclosed |
| US-20050159597-A1 | 3-Quinuclidinyl amino-substituted biaryl derivatives | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
| US-20050137203-A1 | 3-quinuclidinyl amino-substituted biaryl derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
| US-20050137204-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159597-A1 | 3-Quinuclidinyl amino-substituted biaryl derivatives | CHRNA7, CHRNA9, CHRNA1 | LSS 2291/4885MEN1 4420/4885KMT2A 1742/4885 |
| US-20070060588-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | LSS 2160/4885MEN1 4342/4885KMT2A 2389/4885 |
| US-20080064703-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | IDO1, IDO2, HTR3C | LSS 2497/4885MEN1 2223/4885KMT2A 1075/4885 |
| US-20050137204-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | LSS 2160/4885MEN1 4342/4885KMT2A 2389/4885 |
| US-20070275975-A1 | 3-QUINUCLIDINYL AMINO-SUBSTITUTED BIARYL DERIVATIVES | CHRNA7, CHRNA9, CHRNA1 | LSS 2291/4885MEN1 4420/4885KMT2A 1742/4885 |
| US-20050137203-A1 | 3-quinuclidinyl amino-substituted biaryl derivatives | CHRNA9, CHRNA7, CHRNA1 | LSS 2158/4885MEN1 4549/4885KMT2A 2096/4885 |
| US-20050245531-A1 | 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1H-indole; attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease, senile dementia, AIDS dementia, Pick's Disease, dementia associated with Down's syndrome; alpha 7 nAChR ligands modulators | CHRNA7, CHRNA6, CHRNA10 | LSS 1859/4885MEN1 4603/4885KMT2A 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.